厄贝沙坦/氢氯噻嗪复方片治疗原发性高血压的谷峰比值与平滑指数研究  

Study on the T/P ratio and smoothness index of Irbesartan/HCTZ Tablet in the treatment of essential hypertension

作　　者：李鹏[1] 刘勇[1] 吴海松[1] 

机构地区：[1]沈阳市红十字会医院心内科,辽宁沈阳110013

出　　处：《中国医药导报》2010年第24期54-55,共2页China Medical Herald

摘　　要：目的:评价厄贝沙坦/氢氯噻嗪复方片(安博诺)对原发性高血压患者降压作用的稳定性。方法:选取50例2级及2级以上的原发性高血压患者,口服安博诺,每日1片,疗程8周,于服药前后进行24h动态血压监测并计算谷峰比值与平滑指数。结果:治疗8周后,24h平均收缩压和舒张压,白昼平均收缩压和舒张压,夜间平均收缩压和舒张压与治疗前比较均有明显下降,差异具有统计学意义(P<0.01),T/P为收缩压75%,舒张压73%,平滑指数为收缩压(1.36±0.45)mmHg,舒张压(1.27±0.31)mmHg(1mmHg=0.133kPa)。结论:厄贝沙坦/氢氯噻嗪复方片对2级及2级以上原发性高血压具有平稳的降压作用。Objective：To evaluate the smooth control effect of Irbesartan/HCTZ in patients with essential hypertension.Methods：50 patients with moderate and severe essential hypertension were taken orally Irbesartan/HCTZ once a day for 8 weeks.24 hours ambulatory blood pressure monitoring after and before treatment were taken and T/P radio and smoothness index were counted.Results：8 weeks after treatment,compared with before treatment,24 hours systolic blood pressure and 24 hours diastolic blood pressure,day systolic blood pressure and diastolic blood pressure,night systolic blood pressure and diastolic blood pressure had very significantly differences（P0.01）,T/P was systolic blood pressure 75%,diastolic blood pressure was 73%,smoothness index was systolic blood pressure（1.36±0.45）,diastolic blood pressure was（1.27±0.31）.Conclusion：Irbesartan/HCTZ Tablet has smoothly control effect on the patients with moderate and severe essential hypertension.

关 键 词：高血压 厄贝沙坦/氢氯噻嗪复方片 谷峰比值 平滑指数 

分 类 号：R544.1[医药卫生—心血管疾病]